The documentation-gap tier, compared: two aggressive marketers publishing too little — and how to shop when neither shows its work.
The two models
Remedy Meds markets aggressively on price while publishing comparatively little about its clinical workflow, pharmacy sourcing, and full fee stack — the documentation gap itself is the finding so far. It sits in our verification queue, and until that pass completes, no Remedy figure or score appears on this site.
Shed is a marketing-forward entrant whose public materials leave the load-bearing questions — which pharmacies compound, what the maintenance-dose total runs, what the membership terms bind — thinly documented. That thinness is a data point, not a verdict; verification is queued, and no Shed figures are repeated here.
Verified vs pending — read this before the marketing
Neither provider on this page has completed price verification, so this comparison stays structural — business models, pricing architecture, and the questions each must answer — with zero advertised numbers repeated as facts. The only verified figures on this site today sit in the ledger.
Shopping the thin tier
When both sides under-document, comparison collapses into interrogation: the eight questions and CoA request become the entire evaluation, and the speed and completeness of answers becomes the score. A thin-tier provider that answers crisply can outrank a glossy one that stonewalls; one that dodges has answered anyway. Neither Remedy nor Shed has cleared verification — treat every advertised number from either as a claim awaiting its audit.
Go deeper
Full files: Remedy Meds · Shed. Decision tools: the quiz routes by coverage and priorities; the calculator turns any quote into a true 12-month number; the ledger holds every verified figure and every pending slot.